---
title: Ondansetron
category: drug
feed: show
date: 15-05-2023
tags: Drug 
author: Dragoman
---

## Mechanism of Action [^1][^2]
- Ondansetron is a selective 5-HT₃ receptor antagonist which affects the chemoreceptor trigger zone

## Indications [^1][^2]
- Prophylaxis *and* treatment of post-operative nausea and vomiting (PONV).

## Dosage [^1][^3]
- 0.1 

## Complications [^1][^2]
- **Headache:** Number needed to harm (NNH) is 36.
- **QTc Prolongation:** Generally well tolerated. 

## Pharmacokinetics [^2]
- **Onset of Action:** 30 to 60 minutes after oral or IV administration.
- **Metabolism:** Hepatic
- **Elimination Half-life:** 3 to 4 hours.
- **Excretion:** Metabolites are excreted in the urine.

## References
[^1]: Gan, T.J., Belani, K.G., Bergese, S., Chung, F., Diemunsch, P., Habib, A.S., Jin, Z., Kovac, A.L., Meyer, T.A., Urman, R.D., Apfel, C.C., Ayad, S., Beagley, L., Candiotti, K., Englesakis, M., Hedrick, T.L., Kranke, P., Lee, S., Lipman, D., Minkowitz, H.S., Morton, J., Philip, B.K. (2020). Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting.
[^2]: Shafer SL, Rathmell JP, Flood P. (2015). *Stoelting’s Pharmacology and Physiology in Anesthetic Practice.* Fifth edition. Philadelphia: Wolters Kluwer Health.
[^3]: Coté CJ, Lerman J, Anderson BJ. *A Practice of Anesthesia for Infants and Children.* Seventh edition. Philadelphia, PA: Elsevier; 2024.

